News | Oncology Diagnostics | April 25, 2018

El Camino Hospital Performs First U.S. Robotic Lung Cancer Bronchoscopy

Interventional pulmonology team viewed the inside of the lungs and obtained a tissue sample with the Auris Health Monarch Platform

El Camino Hospital Performs First U.S. Robotic Lung Cancer Bronchoscopy

April 25, 2018 — The interventional pulmonology team at the Taft Center for Clinical Research at El Camino Hospital in Mountain View, Calif., successfully performed an innovative robotic bronchoscopy procedure to view the inside of the lungs and obtain a tissue sample. This procedure, the first of its kind performed in the United States, took place as part of a clinical trial of Auris Health’s Monarch Platform. Auris recently announced U.S. Food and Drug Administration (FDA) clearance of the platform.

According to the American Cancer Society, lung cancer is the second most common cancer in both men and women. It is often the leading cause of cancer deaths in the United States, having a higher mortality than prostate, colon and breast cancers combined, according to the ACS. Approximately 220,000 people are newly diagnosed with lung cancer each year and more than 155,000 people die from the disease annually in the United States.

The early and accurate diagnosis of lung cancer is critical. Today, 90 percent of people who have lung cancer die from the disease, in part because it is often not found until the cancer is at an advanced stage. As the technology to identify lesions improves and screening for lung cancer in at-risk individuals advances, there will be increased requirements for minimally invasive diagnosis.

The Monarch Platform integrates the latest advancements in robotics, software, data science and endoscopy, with the goal of enabling earlier and more-accurate diagnosis, and eventually treatment, of small and hard-to-reach nodules in the periphery of the lung.

“At El Camino Hospital, we utilize a variety of minimally invasive procedures to visualize internal structures, obtain tissue samples and diagnose lung disease. With the use of the Monarch Platform, we are embarking on a paradigm shift in how we diagnose suspicious nodules in the lung. Since the robotic bronchoscope has the ability to travel deeper into the lung and precisely guide a biopsy instrument to even the most difficult nodules, the technology offers the potential to diagnose lung cancer at an earlier stage,” stated Ganesh Krishna, M.D., medical director of the Interventional Pulmonology Program at El Camino Hospital and fellowship director of the Interventional Pulmonary Fellowship Program in collaboration with University of California, San Francisco (UCSF) and Palo Alto Medical Foundation.

For more information: www.aurishealth.com

 

Related Content

Numerical simulation with a heterogeneous mouse

Numerical simulation with a heterogeneous mouse. (a) The geometry of the mouse with major organs near the source, and (b) the surface fluence computed with TIM-OS. Image courtesy of Rensselaer Polytechnic Institute.

News | Oncology Diagnostics | September 20, 2019
If researchers could observe drug delivery and its effect on cancer cells in real time, they would be able to tailor...
Screening Mammography Could Benefit Men at High Risk of Breast Cancer
News | Mammography | September 18, 2019
Selective mammography screening can provide potentially lifesaving early detection of breast cancer in men who are at...
Radiation After Immunotherapy Improves Progression-free Survival for Some Metastatic Lung Cancer Patients
News | Lung Cancer | September 18, 2019
Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates...
The Artis icono biplane angiography system is designed for use in neurointerventions and interventional radiology

The Artis icono biplane angiography system is designed for use in neurointerventions and interventional radiology. Image courtesy of Siemens Healthineers.

Technology | Angiography | September 17, 2019
The U.S. Food and Drug Administration (FDA) has cleared the Artis icono, a high-precision family of angiography systems...
FDA Clears GE Healthcare's Critical Care Suite Chest X-ray AI
Technology | X-Ray | September 12, 2019
GE Healthcare announced the U.S. Food and Drug Administration’s (FDA) 510(k) clearance of Critical Care Suite, a...
iCAD's ProFound AI Wins Best New Radiology Solution in 2019 MedTech Breakthrough Awards
News | Computer-Aided Detection Software | September 09, 2019
iCAD Inc. announced MedTech Breakthrough, an independent organization that recognizes the top companies and solutions...
Imaging Biometrics and Medical College of Wisconsin Awarded NIH Grant
News | Neuro Imaging | September 09, 2019
Imaging Biometrics LLC (IB), in collaboration with the Medical College of Wisconsin (MCW), has received a $2.75 million...
Adept Medical Launches Antegrade IR Platform
Technology | Interventional Radiology | September 03, 2019
New Zealand-based Adept Medical announced the launch of the Antegrade IR Platform. Clinically driven, it is placed to...
New Radiomics Model Uses Immunohistochemistry to Predict Thyroid Nodules

Workflow of radiomics analysis for IHC indicators. Yellow lines denote area of analysis; red lines denote ROI for radiomic features extraction. X = original image, L = low-pass filter, H = high-pass filter. Image courtesy of Jiabing Gu, et al.

News | Artificial Intelligence | September 03, 2019
Researchers have validated a first-of-its-kind machine learning–based model to evaluate immunohistochemical (IHC)...
Study Finds Growth in Paracentesis and Thoracentesis Procedures

Image source: Blausen.com staff (2014). "Medical gallery of Blausen Medical 2014". WikiJournal of Medicine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436. [CC BY 3.0 (https://creativecommons.org/licenses/by/3.0)]

News | Interventional Radiology | August 27, 2019 | Jeff Zagoudis, Associate Editor
A new Harvey L. Neiman Health Policy Institute study assesses temporal and patient-level differences in paracentesis...